KPTI Karyopharm Therapeutics Inc.

-0.38  -4%
Previous Close 9.21
Open 9.35
Price To Book 3.13
Market Cap 536050545
Shares 60,707,876
Volume 829,899
Short Ratio
Av. Daily Volume 798,202

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data presented at ASH 2016.
Selinexor - SAIL
Acute myeloid leukemia (AML)
Phase 2 initiated April 2014. Interim data at ASCO 2015
Selinexor - (KING study)
Cancer - glioblastoma
Phase 3 top-line data due end of 2019.
Selinexor - SEAL
Dedifferentiated liposarcoma
PDUFA date under priority review April 6, 2019. Advisory Committee Meeting February 26, 2019 - 12:30pm. Briefing notes likely out February 22.
Quadruple Refractory Multiple Myeloma
Phase 3 data due end of 2019.
Selinexor - BOSTON
Multiple myeloma
NDA filing due 2019.
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 data presented at ASCO 2015. Phase 3 trial to be initiated late 2017.
Selinexor (SIGN Study)
Cancer - Advanced Gynecologic Malignancies (SIGN Study)
Phase 2 trial terminated.
Selinexor - SIRRT
Richter's transformation
Phase 2 trial terminated.
Selinexor - SHIP
Cancer - hormone-refractory prostate cancer (HRPC)
Phase 3 top-line data due 2020.
Selinexor - SIENDO
Endometrial cancer
Phase 2 data due 1H 2019.
Solid tumors
Phase 1/2 updated tolerability data due 2Q 2019.
Non-Hodgkin Lymphoma

Latest News

  1. Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
  2. Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  3. Edited Transcript of KPTI earnings conference call or presentation 8-Nov-18 1:30pm GMT
  4. Karyopharm Files MAA for Myeloma Candidate Selinexor in EU
  5. Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma
  6. How Financially Strong Is Karyopharm Therapeutics Inc. (NASDAQ:KPTI)?
  7. Karyopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference
  8. Karyopharm Therapeutics Inc (KPTI) Hedge Funds Are Snapping Up
  9. Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting
  10. The 4 Healthcare Stocks To Watch On Monday
  11. Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
  12. Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates
  13. Karyopharm Therapeutics: 3Q Earnings Snapshot
  14. Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma